Airway Closure During Extracorporeal Membrane Oxygenation: The AiCLOSE Study

Sponsor
Lorenzo delSorbo (Other)
Overall Status
Recruiting
CT.gov ID
NCT05196074
Collaborator
Unity Health Toronto (Other)
299
1
35.9
8.3

Study Details

Study Description

Brief Summary

About 65,000 Canadians develop acute respiratory failure requiring breathing machines (ventilators) to give oxygen to their lungs. Unfortunately, up to 50% of these individuals will not survive their illness.

Mechanical ventilation through breathing machines, though potentially lifesaving, may further injure the lungs and the respiratory muscles. In the patients with the most severe and life threatening forms of respiratory failure a breathing machine alone may not be able to provide enough oxygen to the lungs and vital organs. In these critical situations, patients may require an artificial lung machine, which is referred to as extracorporeal membrane oxygenation (ECMO) to temporarily replace the function of the patient's own lung and supply critical oxygen to the body, while protecting the damaged lungs. How to use the breathing machine safely while a patient is on ECMO is still unknown. Using conventional breathing machine settings while on ECMO can lead to large portions of the lungs or airway to remain collapsed, which can contribute to further lung damage.

The investigators have recently discovered a way of detecting if patients on a breathing machine suffer from collapsed airways. Knowing if the most severe patients on ECMO have airway collapse is a pivotal question that the investigators plan to answer in our study. The investigators will use our technique to determine how many patients on ECMO have airway closure and determine if this contributes to a longer time on ECMO and a longer time on a breathing machine, and if this impacts a patient's survival in the intensive care unit.

Condition or Disease Intervention/Treatment Phase
  • Other: Acute hypoxemic respiratory failure patients on VV-ECMO

Study Design

Study Type:
Observational
Anticipated Enrollment :
299 participants
Observational Model:
Other
Time Perspective:
Prospective
Official Title:
Airway Closure During Extracorporeal Membrane Oxygenation: The AiCLOSE Study
Actual Study Start Date :
Apr 4, 2022
Anticipated Primary Completion Date :
Apr 1, 2024
Anticipated Study Completion Date :
Apr 1, 2025

Arms and Interventions

Arm Intervention/Treatment
Acute hypoxemic respiratory failure patients on VV-ECMO

Other: Acute hypoxemic respiratory failure patients on VV-ECMO
To describe the prevalence of complete airway closure in patients with acute hypoxemic respiratory failure on VV-ECMO and its association with outcome.

Outcome Measures

Primary Outcome Measures

  1. Prevalence of complete airway closure [Day 1 of VV-ECMO cannulation]

    Prevalence of complete airway closure during day 1 of VV-ECMO support.

Secondary Outcome Measures

  1. Correlation of airway closure with patient outcomes [Up to 90 days from VV-ECMO cannulation]

    Evaluation of the correlation between the presence of complete airway closure and the level of airway opening pressure and both clinical and physiological outcomes listed below: a. Clinical outcomes i. duration of ECMO support at 90 days ii. duration of mechanical ventilation at 90 days iii. ICU mortality iv. mortality at 90 days v. prevalence of barotrauma vi. daily ECMO support I. sweep gas II. Flow vii. Daily fluid balance b. Physiological outcomes i. time to recovery I. In spontaneous modes of ventilation compliance will be measured by dividing tidal volume by driving pressure ii. time to protective spontaneous breathing (defined as: a. ventilator not continuously triggered by the patient I. Pocc is measured by performing an end-expiratory occlusion maneuver, freezing the ventilator waveform and measuring the drop in airway pressure. iii. lung recruitability iv. right ventricular dysfunction

  2. Correlation of the degree of mismatch between clinical PEEP and AOP with patient outcomes [Up to 90 days from VV-ECMO cannulation]

    Evaluation of the correlation between the degree of mismatch between clinical PEEP and AOP and patient outcomes listed below: a. Clinical outcomes i. duration of ECMO support at 90 days ii. duration of mechanical ventilation at 90 days iii. ICU mortality iv. mortality at 90 days v. prevalence of barotrauma vi. daily ECMO support I. sweep gas II. Flow vii. Daily fluid balance b. Physiological outcomes i. time to recovery I. In spontaneous modes of ventilation compliance will be measured by dividing tidal volume by driving pressure ii. time to protective spontaneous breathing (defined as: a. ventilator not continuously triggered by the patient I. Pocc is measured by performing an end-expiratory occlusion maneuver, freezing the ventilator waveform and measuring the drop in airway pressure. iii. lung recruitability iv. right ventricular dysfunction

  3. Assessment of the distribution of airway closure within the lung and between the two lungs [Up to 90 days from VV-ECMO cannulation]

    Assessment of the distribution of airway closure within the lung and between the two lungs by EIT.

  4. Assessment of predictors of airway closure [Up to 90 days from VV-ECMO cannulation]

    Assessment of body mass index and the degree of obesity as predictors of airway closure.

Eligibility Criteria

Criteria

Ages Eligible for Study:
N/A and Older
Sexes Eligible for Study:
All
Accepts Healthy Volunteers:
No
Inclusion Criteria:
  • Acute hypoxemic respiratory failure

  • VV-ECMO

  • Less than 24 hours from ECMO cannulation

Exclusion Criteria:
  • Air leak

  • VV-ECMO as bridge to lung transplantation

  • Status asthmaticus

Contacts and Locations

Locations

Site City State Country Postal Code
1 Toronto General Hospital Toronto Ontario Canada M5G 2N2

Sponsors and Collaborators

  • Lorenzo delSorbo
  • Unity Health Toronto

Investigators

  • Principal Investigator: Lorenzo Del Sorbo, MD, University Health Network, Toronto
  • Principal Investigator: Laurent Brochard, MD, Unity Health Toronto
  • Principal Investigator: Michael Sklar, MD, Unity Health Toronto

Study Documents (Full-Text)

None provided.

More Information

Publications

None provided.
Responsible Party:
Lorenzo delSorbo, MD, Critical Care Medicine Department, Toronto General Hospital, University Health Network, Toronto
ClinicalTrials.gov Identifier:
NCT05196074
Other Study ID Numbers:
  • 21-5784
First Posted:
Jan 19, 2022
Last Update Posted:
May 17, 2022
Last Verified:
May 1, 2022
Individual Participant Data (IPD) Sharing Statement:
No
Plan to Share IPD:
No
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:

Study Results

No Results Posted as of May 17, 2022